Navigation Links
iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development
Date:5/6/2009

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- iZumi Bio, Inc., a biotechnology company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells, today announced the appointments of Berta Strulovici, Ph.D., as chief technology officer (CTO) and Dushyant Pathak, Ph.D., as vice president of Business Development.

"The appointments of Drs. Strulovici and Pathak at iZumi are a critical part of our ability to execute on our business strategy as we continue to expand our management team. Berta's deep drug discovery expertise across a wide range of therapeutic areas and technologies, including stem cell technology, will accelerate iZumi's goal of making drug discovery and development faster, more efficient and informed," said John P. Walker, chief executive officer of iZumi. "Dushyant's proven track record in creating alliances with both pharmaceutical partners and research institutions will be instrumental to iZumi's partnering and commercial strategies."

Prior to joining iZumi, Dr. Strulovici served as vice president, Basic Research at Merck Research Laboratories and head of Automated Biology at Merck & Co. At Merck, she was responsible for molecular target identification and led the worldwide development and execution of the early discovery pipeline across all therapeutic areas. Prior to joining Merck in 1996, she held positions at Tularik, Inc. and Syntex Research. Dr. Strulovici received her Ph.D. from the Weizmann Institute of Science in Israel, and conducted her work as a postdoctoral fellow at the Howard Hughes Medical Institute, Duke University Medical Center.

Dr. Pathak joins iZumi from Cellexicon, Inc., where he served as president and chief business officer. He previously held senior management positions at Renovis, Inc., Centaur Pharma
'/>"/>

SOURCE iZumi Bio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
2. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
3. iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer
4. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
5. Codexis Appoints Singapore Laboratories Managing Director
6. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
10. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... of scientists at Rutgers University has found a material in ... of the material. If the magnetoelectric effect discovered by ... could be useful for manipulating small-scale magnetic bits in ultra ... of Physical Review Letters . The researchers found ...
... A research team co-led by scientists from the J. ... (IGS), University of Maryland School of Medicine, today published the ... ) genome in Nature Biotechnology . Agnes P. Chan, ... on the paper describing the 4.5X coverage of this important ...
... Clinical Efficacy and Safety of Radioembolisation Using... -- BRUSSELS, August 19, 2010 ... ... --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Biology Technology:Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 2Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 3Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 2Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 3Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 4Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 5Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 6Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 7
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Alternating hemiplegia of childhood (AHC) is a very rare ... the body and then the other in devastating bouts ... difficulty walking are common among patients with this diagnosis. ... discovered that mutations in one gene cause the disease ...
... Branch at Galveston researchers have been awarded a two-year, $1.25 ... of custom-growing human lung tissue to make a three-dimensional model ... the size of a dime, will form the core of ... testing new vaccines and drugs and studying disease processes in ...
... This press release is available in German . ... perceive our world in a self-reflective manner is difficult to ... sleep, however, we are not. But there are people, known ... sleep. Studies employing magnetic resonance tomography (MRT) have now been ...
Cached Biology News:Gene discovery set to help with mysterious paralysis of childhood 2Gene discovery set to help with mysterious paralysis of childhood 3UTMB scientists awarded NIH grant for lab-grown lung tissue project 2The seat of meta-consciousness in the brain 2
... anti-freeze environment for enzyme conjugated antibodies and ... viscosity solution at -20C , No ... is convenient , Contains preservatives to ... Protect enzyme conjugates during storage without the ...
Request Info...
... Tecans GenePaint system, which is based on ... steps required for performing in situ hybridization of ... key step in the study of gene expression, ... cells and tissues and can be used to ...
... The Microarray Gene Frame® has ... hybridisations. These frames feature the same ... standard Gene Frame® range for easy ... hybridisation uniformity and there are three ...
Biology Products: